Genocea Biosciences, Inc.
GNCA
GNCA was delisted on the 2nd of June, 2022.
65 hedge funds and large institutions have $56.4M invested in Genocea Biosciences, Inc. in 2018 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 6 reducing their positions, and 8 closing their positions.
475% more capital invested
Capital invested by funds: $9.81M → $56.4M (+$46.6M)
350% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 6
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
16% more funds holding
Funds holding: 56 → 65 (+9)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$26M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$8.49M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$5.19M |
| 4 |
BlackRock
New York
|
+$2.58M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
-$912K |
| 2 |
AA
AlphaMark Advisors
Ft. Wright,
Kentucky
|
-$282K |
| 3 |
VF
Virtu Financial
New York
|
-$191K |
| 4 |
Millennium Management
New York
|
-$145K |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$83.7K |
GNCA Hedge Fund Activity: Q1 2018 in Review
65 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Genocea Biosciences, Inc. (GNCA) for Q1 2018, worth a combined $56.4M — up 475% from $9.81M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new GNCA positions and 8 closed out — a net gain of 9 holders — while 27 added to existing stakes and 6 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $26M. The largest seller was Northpointe Capital, exiting entirely with an estimated $912K sold.
- 65 institutional investors held Genocea Biosciences, Inc. (GNCA) as of Q1 2018, up from 56 in Q4 2017.
- Funds reported $56.4M of Genocea Biosciences, Inc. stock for Q1 2018, up 475% quarter-over-quarter.
- 17 funds opened new Genocea Biosciences, Inc. positions in Q1 2018 and 8 closed out, a net change of +9 holders.
- The largest Genocea Biosciences, Inc. buyer in Q1 2018 was NEA Management Company, an estimated $26M added.
- The largest Genocea Biosciences, Inc. seller in Q1 2018 was Northpointe Capital, an estimated $912K sold.
Based on aggregated 13F filings for Q1 2018.